Age: 0.13
Sex: M
Vaccine: DTPHIB, HEP, IPV, HIBV, MMR
Symptoms: Neurodevelopmental disorder
Clinical narrative: Information has been received regarding a case in litigation concerning a minor male pt who was exposed to high levels of mercury from thimerosal through exposure to unspecified products. In additional, the pt was exposed to mercury from continually inhaling and ingesting industry mercury emissions from fossil fuel driven power plants. The mercury included in thimerosal laden products and power plant emissions together caused the pt to suffer from serious and permanent neurological injuries. The pt was exposed to airborne mercury vapor and mercury through food chain. The exposure to airborne mercury in the environment through inhalation, the food chain, and other sources contributed to the cumulative mercury toxicity and was a substantial factor in causing his neurological damage. it was noted that the pt had a heightened vulnerability to suffer neurological injuries from industrial mercury as a direct result of thimerosal exposure. As a direct and proximate cause of the toxic mercury exposure to  the pt, minor male was caused to suffer serious and permanent neurological damage which included past and future mental, intellectual, development and neurological incapacity and associated learning disabilities, disorders and impairments. Upon internal review, cumulative mercury toxicity were considered to be an other important medical event (OMIC). Follow up information has been received from medical records concerning an approx 20 month old male with a mild allergy who on 12/10/1993 and 1/26/1994 was vaccinated with a first and second dose of hepatitis B virus vaccine rHBsAg yeast (manufacturer unk), respectively. Suspect concomitant therapy given on 4/6/1995 and 8/12/1998 included a first and second dose of MMR II (second dose lot 624114/0955H. Other concomitant therapy included a first dose of diphtheria toxoid + Hib conj vaccine + pertussis whole cell vaccine + tetanus toxoid  (Tetramune vaccine) and polio virus vaccine. On 8/24/1995, the pt was evaluated by a physician for developmental and language delay. His parents described their concerns as being predominantly his failure to make progress in language and understanding. Solitariness and lack of interest in his surroundings. The physician noted significant delays. At 20 months of age, his development was at least 5-6 months behind. His receptive and expressive language was even more seriously affected. Other concerning issues are his lack of socialization. On 11/16/1995, the pt was seen again by his physician. The pt was diagnosed with Pervasive developmental delay. The recommendations involved placement in an appropriately aged preschool or program with a teacher familiar with autism. Strong emphasis should be placed on social skills and development of communication skills He should have added speech and language therapy. On 12/8/1997, the pt had an MRI of the brain showed mild left and right moderate right mastoid inflammation disease and mild posterior bilateral ethmoid inflammatory disease and minimal right maxillary sinus inflammatory disease. On 7/7/04 the pt was vaccinated with a third dose of hepatitis B virus vaccine rHBsAg yeast (manufacturer unk) and tuberculin purified protein derivative. At the time of this report the pt had not recovered from Pervasive Developmental Delay. The pt also experienced recurrent ear infection (treated with PE tubes) and bilateral inguinal hernias (treated with bilateral inguinal herniorrhaphy), chicken pox, viral illness and fever, upper respiratory infection, sleep difficulties adn nasal obstruction, physiologic hyperopia, bed wetting, constipation and abdominal pain, cervical fusion, cough and wheezing. No further information is available. All medical records are available upon request.